ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.
Thu, 25 Jul 2024 08:02:00 GMT Anglo-Swedish drugmaker AstraZeneca raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare ...
Tue, 23 Jul 2024 19:00:19 GMT Thank you for standing by for the Alphabet second quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a ...
Tue, 23 Jul 2024 17:05:00 GMT During this call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP measures is included in today's earnings press release which is distributed and ...
Mon, 22 Jul 2024 22:38:00 GMT The fluorotelomers market is estimated to increase at an 11% Compound Annual Growth Rate (CAGR) between 2023 and 2033. In the previous four-year period from 2018 to 2022, the observed CAGR was 3.4%, ...
